The latest cancer drugs news
Browsing: Cancer Drug News
Nivolumab subcutaneous formulation given approval across multiple solid tumour types in the UK
Bristol Myers Squibb (BMS) has announced that the UK Medicines and Healthcare products Regulatory Agency…
New study highlights success of Financial Toxicity Tumour Board in reducing cancer treatment costs
Financial toxicity, the financial distress linked to cancer treatment, significantly impacts patient outcomes. To combat…
FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma
On April 23, 2025, the Food and Drug Administration approved penpulimab-kcqx with cisplatin or carboplatin…
NICE approves dual immunotherapy for the first line treatment of adult patients with mismatch repair deficient or microsatellite instability high unresectable or metastatic colorectal cancer approved in the UK
Nivolumab in combination with ipilimumab has been granted an indication extension in the UK by…
Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: Hint of major added benefit
Urothelium is the term for the mucous membrane that lines the urinary tract. This includes…
How oncologists respond to negative trials
FDA Withdrawals and Oncology Drug Use The U.S. Food and Drug Administration’s (FDA) accelerated approval…
FDA approves cabozantinib for adults and paediatric patients 12 years of age and older with pNET and epNET
On March 26, 2025, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for…
FDA approves dual-action drug for patients with previously treated advanced neuroendocrine tumours
Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug…
FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)
On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab with…
FDA approves vimseltinib for symptomatic tenosynovial giant cell tumour
On February 14, 2025, the Food and Drug Administration approved vimseltinib, a kinase inhibitor, for…